BIOTECH ASSISTANT / FIELD NOTES

Covalent BTK degrader study challenges the need for catalytic turnover

Academic source · Nature Communications

Source published:

Site published: 2026-11-03 · Updated: 2026-11-03

Explore this article with AI

This source is linked automatically. Choose a question to get started.

Ask AI ↗

What changed

Researchers characterized PSIRC3, an irreversible covalent BTK PROTAC that produced rapid, selective degradation in cellular experiments and target reduction in vivo. Activity required engagement of BTK Cys481 and was lost against the C481S mutant. Modeling supported a balance between target and E3 ligase affinities, challenging the assumption that catalytic turnover is required for potent degradation.

Why it may matter

The work expands covalent degrader design options while underscoring mutation sensitivity and affinity-related hook effects as practical optimization constraints in preclinical discovery.

The interpretation above is analysis, not a conclusion attributed to the original source.

Read the original source ↗

Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections

Protein degradation / PROTAC

Related updates

Amphista Therapeutics / Business Wire

Amphista previews BRD9 degradation findings and BRAMLIE trial design at ASH

Amphista announced an ASH oral presentation on AMX-883-mediated BRD9 degradation, describing disruption of hematopoietic transcriptional programs, myeloid differentiation, and reduced leukemic stem-cell frequency in experimental work. A separate abstract outlines the ongoing Phase 1 BRAMLIE study in AML and high-risk myelodysplastic syndrome. The announcement does not establish clinical efficacy for AMX-883.

Proceedings of the National Academy of Sciences / PubMed

Bispecific protein drives dual receptor degradation in mouse eye-disease models

A PNAS study reports RHV, a tetravalent bispecific protein designed to internalize and lysosomally degrade VCAM-1 and VEGFR on pathological vessels. The original abstract describes activity in mouse choroidal neovascularization models, including efficacy comparable to aflibercept at one-quarter of the molar dose. This is preclinical extracellular receptor degradation, distinct from an intracellular small-molecule PROTAC.

Continue your research

Explore company filters, side-by-side comparisons, private bookmarks, and member discussions.

Open free member tools ↗
AI assistant ↗